JP2012516855A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012516855A5 JP2012516855A5 JP2011548426A JP2011548426A JP2012516855A5 JP 2012516855 A5 JP2012516855 A5 JP 2012516855A5 JP 2011548426 A JP2011548426 A JP 2011548426A JP 2011548426 A JP2011548426 A JP 2011548426A JP 2012516855 A5 JP2012516855 A5 JP 2012516855A5
- Authority
- JP
- Japan
- Prior art keywords
- bismuth
- bis
- thiol
- composition
- antibiotics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BIGYLAKFCGVRAN-UHFFFAOYSA-N 1,3,4-thiadiazolidine-2,5-dithione Chemical compound S=C1NNC(=S)S1 BIGYLAKFCGVRAN-UHFFFAOYSA-N 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 16
- 230000003115 biocidal Effects 0.000 claims 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 10
- 210000000981 Epithelium Anatomy 0.000 claims 8
- 244000052616 bacterial pathogens Species 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 8
- 150000003573 thiols Chemical class 0.000 claims 8
- 239000003242 anti bacterial agent Substances 0.000 claims 7
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 claims 7
- 229910052797 bismuth Inorganic materials 0.000 claims 7
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 6
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 6
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 6
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 6
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 6
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 6
- 230000002378 acidificating Effects 0.000 claims 6
- 239000007864 aqueous solution Substances 0.000 claims 6
- 229940079866 intestinal antibiotics Drugs 0.000 claims 6
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 6
- 239000000243 solution Substances 0.000 claims 6
- -1 BT compound Chemical class 0.000 claims 5
- ZREIPSZUJIFJNP-UHFFFAOYSA-K Bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 claims 5
- 239000011859 microparticle Substances 0.000 claims 5
- VHJLVAABSRFDPM-ZXZARUISSA-N Dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 229940079593 drugs Drugs 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 241000588724 Escherichia coli Species 0.000 claims 3
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 229960003085 meticillin Drugs 0.000 claims 3
- 230000002195 synergetic Effects 0.000 claims 3
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-Ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 claims 2
- ZJLMKPKYJBQJNH-UHFFFAOYSA-N 1,3-Propanedithiol Chemical compound SCCCS ZJLMKPKYJBQJNH-UHFFFAOYSA-N 0.000 claims 2
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dimercaptobutane-2,3-diol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- FETFXNFGOYOOSP-UHFFFAOYSA-N 1-sulfanylpropan-2-ol Chemical compound CC(O)CS FETFXNFGOYOOSP-UHFFFAOYSA-N 0.000 claims 2
- NIAAGQAEVGMHPM-UHFFFAOYSA-N 4-methylbenzene-1,2-dithiol Chemical compound CC1=CC=C(S)C(S)=C1 NIAAGQAEVGMHPM-UHFFFAOYSA-N 0.000 claims 2
- WQABCVAJNWAXTE-UHFFFAOYSA-N Dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 claims 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims 2
- 229920001609 Poly(3,4-ethylenedioxythiophene) Polymers 0.000 claims 2
- SUVIGLJNEAMWEG-UHFFFAOYSA-N Propanethiol Chemical compound CCCS SUVIGLJNEAMWEG-UHFFFAOYSA-N 0.000 claims 2
- 229940055023 Pseudomonas aeruginosa Drugs 0.000 claims 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 2
- 229940076185 Staphylococcus aureus Drugs 0.000 claims 2
- 241000191967 Staphylococcus aureus Species 0.000 claims 2
- 229940037645 Staphylococcus epidermidis Drugs 0.000 claims 2
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 2
- 229960000707 Tobramycin Drugs 0.000 claims 2
- NLVFBUXFDBBNBW-PBSUHMDJSA-N Tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims 2
- MYPYJXKWCTUITO-LYRMYLQWSA-N VANCOMYCIN Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 claims 2
- 229960003165 Vancomycin Drugs 0.000 claims 2
- 108010059993 Vancomycin Proteins 0.000 claims 2
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims 2
- TWWSEEHCVDRRRI-UHFFFAOYSA-N butane-2,3-dithiol Chemical compound CC(S)C(C)S TWWSEEHCVDRRRI-UHFFFAOYSA-N 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 239000003153 chemical reaction reagent Substances 0.000 claims 2
- 239000012530 fluid Substances 0.000 claims 2
- 229960002518 gentamicin Drugs 0.000 claims 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000002244 precipitate Substances 0.000 claims 2
- FGVVTMRZYROCTH-UHFFFAOYSA-N pyridine-2-thiol N-oxide Chemical compound [O-][N+]1=CC=CC=C1S FGVVTMRZYROCTH-UHFFFAOYSA-N 0.000 claims 2
- 229960002026 pyrithione Drugs 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 230000004083 survival Effects 0.000 claims 2
- 201000008827 tuberculosis Diseases 0.000 claims 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Substances OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims 1
- 229950006334 APRAMYCIN Drugs 0.000 claims 1
- MKKYBZZTJQGVCD-XTCKQBCOSA-N ARBEKACIN Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)CC[C@H]1N MKKYBZZTJQGVCD-XTCKQBCOSA-N 0.000 claims 1
- 241000588626 Acinetobacter baumannii Species 0.000 claims 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 claims 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
- XZNUGFQTQHRASN-XQENGBIVSA-N Apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 claims 1
- 241000271566 Aves Species 0.000 claims 1
- 241000193738 Bacillus anthracis Species 0.000 claims 1
- 210000004556 Brain Anatomy 0.000 claims 1
- 229960005091 Chloramphenicol Drugs 0.000 claims 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims 1
- 241000193163 Clostridioides difficile Species 0.000 claims 1
- 210000004207 Dermis Anatomy 0.000 claims 1
- 229960003722 Doxycycline Drugs 0.000 claims 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 claims 1
- 241000588697 Enterobacter cloacae Species 0.000 claims 1
- 229940119563 Enterobacter cloacae Drugs 0.000 claims 1
- 210000002615 Epidermis Anatomy 0.000 claims 1
- 229940109526 Ery Drugs 0.000 claims 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims 1
- 229940037467 Helicobacter pylori Drugs 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N Kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229940045505 Klebsiella pneumoniae Drugs 0.000 claims 1
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 1
- 229940115932 Legionella pneumophila Drugs 0.000 claims 1
- 241000589242 Legionella pneumophila Species 0.000 claims 1
- AGBQKNBQESQNJD-SSDOTTSWSA-N Lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims 1
- 210000000214 Mouth Anatomy 0.000 claims 1
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N Nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 claims 1
- 229940049954 Penicillin Drugs 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 229950009506 Penicillinase Drugs 0.000 claims 1
- 108010087702 Penicillinase Proteins 0.000 claims 1
- 206010035148 Plague Diseases 0.000 claims 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims 1
- 241000607768 Shigella Species 0.000 claims 1
- 206010040550 Shigella infection Diseases 0.000 claims 1
- 241000295644 Staphylococcaceae Species 0.000 claims 1
- 229960005322 Streptomycin Drugs 0.000 claims 1
- 241000607626 Vibrio cholerae Species 0.000 claims 1
- 241000607479 Yersinia pestis Species 0.000 claims 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N Zygomycin A1 Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 claims 1
- 229960004821 amikacin Drugs 0.000 claims 1
- 229960000723 ampicillin Drugs 0.000 claims 1
- 229960005397 arbekacin Drugs 0.000 claims 1
- 229960000626 benzylpenicillin Drugs 0.000 claims 1
- 230000032770 biofilm formation Effects 0.000 claims 1
- ZPBUXMCXNANBKA-UHFFFAOYSA-N bismuth;1-sulfanylpropan-2-ol Chemical compound [Bi].CC(O)CS ZPBUXMCXNANBKA-UHFFFAOYSA-N 0.000 claims 1
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 238000007598 dipping method Methods 0.000 claims 1
- 201000009910 diseases by infectious agent Diseases 0.000 claims 1
- 230000000688 enterotoxigenic Effects 0.000 claims 1
- 239000010419 fine particle Substances 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000002262 irrigation Effects 0.000 claims 1
- 238000003973 irrigation Methods 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 235000019136 lipoic acid Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229960000515 nafcillin Drugs 0.000 claims 1
- 229960004927 neomycin Drugs 0.000 claims 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 claims 1
- 229960001914 paromomycin Drugs 0.000 claims 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
- 229960002663 thioctic acid Drugs 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 230000000699 topical Effects 0.000 claims 1
Claims (26)
- ビスマス‐チオール(BT)組成物であって、前記組成物が粒子サイズアナライザで分析される際に単峰形のサイズ分布を呈し、かつ微粉化、粉砕又は超臨界流体処理をされていないビスマス‐チオール(BT)を含む複数の固体微小粒子を含み、実質的に全ての前記微小粒子が約0.4μm〜約5μmの体積平均径を有し、前記BT化合物が、ビスマスまたはビスマス塩およびチオール含有化合物を含む、ビスマス‐チオール組成物。
- (a)実質的に固形の沈降物が含まれていない溶液を得るために十分な条件および時間の下(i)
少なくとも50mMの濃度でビスマスを含むビスマス塩を含み、かつ親水性、極性又は有機溶解剤を含まない酸性水溶液と(ii)体積で約25%のエタノールを含む混合物を得るに十分な量のエタノールとを混合する工程;および、
(b)前記(a)の混合物にチオール含有化合物を含むエタノール溶液を添加して反応液を得る工程であって、前記チオール含有化合物が、前記BT化合物を含有する前記微粒子を含む沈殿物の形成に十分な条件および時間の下、前記ビスマスに対してモル比で約1:3〜約3:1にて前記反応液中に存在する工程、
を含む工程によって形成される請求項1に記載のビスマス‐チオール組成物。
- 前記ビスマス塩がBi(NO3)3である、請求項2に記載のビスマス‐チオール組成物。
- 前記酸性水溶液が重量で少なくとも5%、10%、15%、20%、22%または22.5%のビスマスを含む、請求項2に記載のビスマス‐チオール組成物。
- 前記酸性水溶液が重量で少なくとも0.5%、1%、1.5%、2%、2.5%、3%、3.5%、4%、4.5%、または5%の硝酸を含む、請求項2に記載のビスマス‐チオール組成物。
- 前記チオール含有化合物が1,2−エタンジチオール、2,3−ジメルカプトプロパノール、ピリチオン、ジチオエリスリトール、3,4−ジメルカプトトルエン、2,3−ブタンジチオール、1,3-プロパンジチオール、2−ヒドロキシプロパンチオール、1−メルカプト−2−プロパノール、ジチオエリスリトール、α−リポ酸およびジチオスレイトールからなる群から選択される1つ以上の試薬を含む、請求項2に記載のビスマス‐チオール組成物。
- ビスマス‐チオール組成物を調整する方法であって、前記組成物が粒子サイズアナライザで分析される際に単峰形のサイズ分布を呈し、かつ微粒子化、粉砕、または超臨界流体処理をされていない、ビスマス-チオール(BT)化合物を含む複数の固体微小粒子を含み、実質的に全ての前記微小粒子が約0.4μm〜約5μmの体積平均径を有し、
(a)実質的に固形の沈降物が含まれていない溶液を得るために十分な条件および時間の下、(i)少なくとも50mMの濃度でビスマスを含むビスマス塩を含み、かつ親水性、極性又は有機溶解剤を含まない酸性水溶液と(ii)体積で約25%のエタノールを含む混合物を得るに十分な量のエタノールとを混合する工程;および
(b)前記(a)の混合物にチオール含有化合物を含むエタノール溶液を添加して反応液を得る工程であって、前記チオール含有化合物が、前記BT化合物を含有する前記微小粒子を含む沈降物の形成に十分な条件および時間の下前記ビスマスに対してモル比で約1:3〜約3:1にて前記反応液中に存在する工程、
を含む方法。
- 不純物を除去するために前記沈降物を回収することを更に含む、請求項7に記載の方法。
- 前記ビスマス塩がBi(NO3)3である、請求項7に記載の方法。
- 前記酸性水溶液が重量で少なくとも5%、10%、15%、20%、22%または22.5%のビスマスを含む、請求項7に記載の方法。
- 前記酸性水溶液が重量で少なくとも0.5%、1%、1.5%、2%、2.5%、3%、3.5%、4%、4.5%、または5%の硝酸を含む、請求項7に記載の方法。
- 前記チオール含有化合物が1,2−エタンジチオール、2,3−ジメルカプトプロパノール、ピリチオン、ジチオエリスリトール、3,4−ジメルカプトトルエン、2,3−ブタンジチオール、1,3-プロパンジチオール、2−ヒドロキシプロパンチオール、1−メルカプト−2−プロパノール、ジチオエリスリトール、ジチオスレイトールおよびα−リポ酸からなる群から選択される1つ以上の試薬を含む、請求項7に記載の方法。
- 細菌性病原体に対して上皮組織表面を保護するための方法であって、前記上皮組織表面と有効量の請求項1に記載のBT組成物とを
(i)前記細菌性病原体による前記上皮組織表面の感染予防、
(ii)前記細菌性病原体の実質的に全プランクトン様細胞の細胞生存または細胞増殖の阻害、
(iii)前記細菌性病原体によるバイオフィルム形成の阻害、および、
(iv)前記細菌性病原体の実質的に全バイオフィルム形態細胞のバイオフィルム生存またはバイオフィルム成長の阻害、
の1つ以上のために、十分な条件および時間で接触せしめる薬剤。
- 前記細菌性病原菌が黄色ブドウ球菌(S.aureus)、MRSA(メチシリン耐性黄色ブドウ球菌)、表皮ブドウ球菌、MRSE(メチシリン耐性表皮ブドウ球菌)、結核菌、鳥結核菌、緑膿菌、薬剤耐性緑膿菌、大腸菌、腸管毒素原性大腸菌、腸管出血性大腸菌、肺炎桿菌、クロストリジウム・ディフィシル、ヘリコバクター・ピロリ、レジオネラ・ニューモフィラ、大便連鎖球菌、メチシリン受容性大便連鎖球菌、エンテロバクター・クロアカエ、ネズミチフス菌、尋常変形菌、エンテロコリチカ菌、ビブリオ・コレラ、フレキシナ赤痢菌、バンコマイシン耐性腸球菌(VRE)、セパシア菌群、野兎病菌、炭疽菌、ペスト菌、緑膿菌、およびアシネトバクター・バウマンニから成る群から選択される、請求項13に記載の薬剤。
- 前記細菌性病原菌が抗生物質耐性を呈する、請求項13に記載の薬剤。
- 前記細菌性病原菌がメチシリン、バンコマイシン、ナフシリン、ゲンタマイシン、アンピシリン、クロラムフェニコール、ドキシサイクリンおよびトブラマイシンからなる群から選択される抗生物質に耐性を呈する、請求項13に記載の薬剤。
- 前記上皮組織表面が表皮、真皮、気道、胃腸管および腺性ライニングからなる群から選択される組織を含む、請求項13に記載の薬剤。
- 前記接触工程が1回または複数回実行される、請求項13に記載の薬剤。
- 少なくとも1つの接触工程が前記上皮組織表面に噴霧、灌注、浸漬、および塗布することのうちの1つを含む、請求項18に記載の薬剤。
- 少なくとも1つの接触工程が吸入、摂取、および経口灌注のうちの1つを含む、請求項18に記載の薬剤。
- 少なくとも1つの接触工程、局所、腹腔内、経口、非経口、静脈内、動脈内、経皮、舌下、皮下、筋肉内、経口腔、鼻腔内、経吸入、眼内圧、耳介内、脳室内、皮下、脂肪内、関節内、および髄腔内から選択される経路の投与を含む、請求項18に記載の薬剤。
- 前記BT組成物がBisBAL、BisEDT、Bis−ジメルカプロール、Bis−DTT、Bis−2−メルカプトエタノール、Bis−DTE、Bis−Pyr、Bis−Ery、Bis−Tol、Bis−BDT、Bis−PDT、Bis−Pyr/Bal、Bis−Pyr/BDT、Bis−Pyr/EDT、Bis−Pyr/PDT、Bis−Pyr/Tol(Bis−Pyr/Ery)、ビスマス−1−メルカプト−2−プロパノールおよびBis−EDT/2−ヒドロキシ−1−プロパンジオールからなる群から選択される1つ以上のBT化合物を含む、請求項13に記載の薬剤。
- 前記上皮組織表面を相乗作用のある抗生物質と、同時にまたは順次に接触せしめること、及び、前記上皮組織表面をBT組成物と接触させる工程に関して任意の順序で接触させることを更に含む、請求項13に記載の薬剤。
- 前記相乗作用のある抗生物質がアミノグリコシド抗生物質、カルバペネム抗生物質、セファロスポリン抗生物質、フルオロキノロン抗生物質、グリコペプチド抗生物質、リンコサミド抗生物質、ペニシリナーゼ耐性ペニシリン抗生物質およびアミノペニシリン抗生物質からなる群から選択される抗生物質を含む、請求項23に記載の薬剤。
- 前記相乗作用のある抗生物質がアミカシン、アルベカシン、ゲンタマイシン、カナマイシン、ネオマイシン、ネチルマイシン、パロモマイシン、ロドストレプトマイシン、ストレプトマイシン、トブラマイシンおよびアプラマイシンからなる群から選択されるアミノグリコシド系抗生物質である、請求項24に記載の薬剤。
- 実質的に明細書本文に記載し図面に示した通りの方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14959309P | 2009-02-03 | 2009-02-03 | |
US61/149,593 | 2009-02-03 | ||
PCT/US2010/023108 WO2010091124A2 (en) | 2009-02-03 | 2010-02-03 | Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014182123A Division JP2015007113A (ja) | 2009-02-03 | 2014-09-08 | 上皮組織、急性および慢性創傷、細菌性バイオフィルムならびに他の適応症のための消毒剤としてのビスマス−チオール |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2012516855A JP2012516855A (ja) | 2012-07-26 |
JP2012516855A5 true JP2012516855A5 (ja) | 2013-03-21 |
JP5674684B2 JP5674684B2 (ja) | 2015-02-25 |
Family
ID=42542638
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011548426A Active JP5674684B2 (ja) | 2009-02-03 | 2010-02-03 | 上皮組織、急性および慢性創傷、細菌性バイオフィルムならびに他の適応症のための消毒剤としてのビスマス−チオール |
JP2014182123A Pending JP2015007113A (ja) | 2009-02-03 | 2014-09-08 | 上皮組織、急性および慢性創傷、細菌性バイオフィルムならびに他の適応症のための消毒剤としてのビスマス−チオール |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014182123A Pending JP2015007113A (ja) | 2009-02-03 | 2014-09-08 | 上皮組織、急性および慢性創傷、細菌性バイオフィルムならびに他の適応症のための消毒剤としてのビスマス−チオール |
Country Status (9)
Country | Link |
---|---|
US (5) | US8389021B2 (ja) |
EP (2) | EP2393491B1 (ja) |
JP (2) | JP5674684B2 (ja) |
CN (1) | CN102341105B (ja) |
AU (1) | AU2010210620B2 (ja) |
BR (1) | BRPI1007885A2 (ja) |
CA (1) | CA2751386C (ja) |
HK (1) | HK1166707A1 (ja) |
WO (1) | WO2010091124A2 (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE112008001301T5 (de) | 2007-05-14 | 2010-04-29 | Reserach Foundation Of State University Of New York | Induktion einer physiologischen Dispersions-Antwort in Bakterien-Zellen in einem Biofilm |
EP2349209A2 (en) | 2008-09-26 | 2011-08-03 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
US9028878B2 (en) | 2009-02-03 | 2015-05-12 | Microbion Corporation | Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses |
EP2393491B1 (en) | 2009-02-03 | 2020-04-22 | Microbion Corporation | Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications |
US9408393B2 (en) | 2010-02-03 | 2016-08-09 | Microbion Corporation | Bismuth-thiols as antiseptics for agricultural, industrial and other uses |
KR102074444B1 (ko) * | 2010-02-03 | 2020-02-06 | 마이크로비온 코포레이션 | 세균 균막의 치료 및 다른 용도를 포함하는, 생의학적 용도를 위한 방부제로서 비스무트-티올 |
CN103079557A (zh) * | 2010-02-03 | 2013-05-01 | 微生物公司 | 作为抗菌剂用于包括细菌生物膜的治疗的生物医学用途以及其它用途的铋-硫醇 |
JP6025712B2 (ja) | 2010-05-12 | 2016-11-16 | レンペックス・ファーマシューティカルズ・インコーポレイテッド | テトラサイクリン組成物 |
DE102010049114A1 (de) * | 2010-10-22 | 2012-04-26 | Schülke & Mayr GmbH | Mit einer antimikrobiellen Wirkstofflösung getränktes textiles Flächengebilde zur Anwendung auf belebten Oberflächen |
DE102010049113A1 (de) * | 2010-10-22 | 2012-04-26 | Schülke & Mayr GmbH | Mit einer antimikrobiellen Wirkstoffzubereitung getränktes textiles Flächengebilde mit einem Trägermaterial auf Basis von Polyolefin |
GB201021186D0 (en) * | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
US9572774B2 (en) | 2011-05-19 | 2017-02-21 | Savara Inc. | Dry powder vancomycin compositions and associated methods |
US20140099380A1 (en) | 2012-06-28 | 2014-04-10 | Ansun Biopharma, Inc. | Microparticle Formulations for Delivery to the Lower and Central Respiratory Tract and Methods of Manufacture |
EP2877204A2 (en) * | 2012-06-28 | 2015-06-03 | Ansun Biopharma, Inc. | Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture |
US9125892B2 (en) | 2014-02-03 | 2015-09-08 | George D. Petito | Composition for reduced scar formation of wounds |
US20150352064A1 (en) * | 2014-06-10 | 2015-12-10 | Kuwait University | Method of treating delayed healing of a wound associated with diabetes |
US9492374B2 (en) * | 2015-03-25 | 2016-11-15 | Jose Rafael Salinas Andrade | Composition and method for treatment of ulcers |
CN104982456B (zh) * | 2015-07-20 | 2017-05-24 | 国家林业局泡桐研究开发中心 | 一种仁用杏推迟开花的方法及推迟开花溶液及其制备方法 |
WO2017145142A1 (en) | 2016-02-25 | 2017-08-31 | Nobio Ltd. | Micro and nanoparticulate compositions comprising anti-microbially active groups |
AU2017278022B2 (en) | 2016-03-30 | 2023-07-06 | Synovo Gmbh | Detecting microbial infection in wounds |
GB201609940D0 (en) * | 2016-06-07 | 2016-07-20 | Novabiotics Ltd | Microparticles |
US10905660B2 (en) | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
IL263540B2 (en) * | 2016-06-07 | 2023-07-01 | Novabiotics Ltd | Microparticles that include a sulfur-containing compound |
WO2018081740A1 (en) * | 2016-10-28 | 2018-05-03 | The Regents Of The University Of California | Tumescent antibiotic injection for treatment of chronic skin and soft tissue infections |
JP7337778B2 (ja) | 2017-08-30 | 2023-09-04 | ノビオ リミテッド | 抗微生物粒子を含む組成物および医療機器 |
US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
JP2021533193A (ja) | 2018-07-31 | 2021-12-02 | マイクロビオン コーポレーション | ビスマスチオール組成物及び使用方法 |
KR20210080350A (ko) * | 2018-07-31 | 2021-06-30 | 마이크로비온 코포레이션 | 상처 치료를 위한 비스무트-티올 조성물 및 방법 |
US11976256B2 (en) | 2018-12-13 | 2024-05-07 | Dow Global Technologies Llc | Liquid laundry detergent formulation |
CN113840901B (zh) | 2019-06-14 | 2023-10-13 | 陶氏环球技术有限责任公司 | 清洁增强剂聚合物 |
WO2020251766A1 (en) | 2019-06-14 | 2020-12-17 | Dow Global Technologies Llc | Liquid laundry detergent with cleaning booster |
CN110237255B (zh) * | 2019-07-02 | 2021-10-22 | 首都医科大学 | 靶向肿瘤细胞的给药体系及其制备方法及应用 |
US20230124862A1 (en) * | 2020-03-24 | 2023-04-20 | Jeffrey W. MILLARD | Bismuth thiol compounds and compositions and methods of treating microbial co-infections |
CN113969300A (zh) * | 2020-07-23 | 2022-01-25 | 启迪禾美生物科技(嘉兴)有限公司 | 一种桉树叶复合活性提取物工艺及其抗菌应用 |
WO2022072842A1 (en) * | 2020-10-01 | 2022-04-07 | Microbion Corporation | Methods of treating bone infections |
CN112426515A (zh) * | 2020-11-30 | 2021-03-02 | 唐芳艳 | 一种用于修复烧伤皮肤的医用面膜 |
WO2022159881A1 (en) * | 2021-01-25 | 2022-07-28 | Microbion Corporation | Amorphous form of bismuth-1,2-ethanedithiol and methods of making |
KR20240013205A (ko) * | 2021-05-26 | 2024-01-30 | 스티븐 바라노위츠 | 방사선 보호를 위한 방법 및 조성물 |
US20230233477A1 (en) * | 2022-01-27 | 2023-07-27 | Kent State University | Bi2O3 NANOPARTICLES PREPARED BY THE TOP-DOWN ULTRASONICATION ROUTE AS A BROAD-SPECTRUM ANTIMICROBIAL TO OVERCOME DRUG RESISTANCE IN ANTIBIOTICS |
CN116440282B (zh) * | 2023-05-09 | 2023-10-20 | 中海生物制药(泰州)有限公司 | 一种鸡传染性支气管炎活疫苗冻干保护剂及其制备方法 |
Family Cites Families (86)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2809971A (en) | 1955-11-22 | 1957-10-15 | Olin Mathieson | Heavy-metal derivatives of 1-hydroxy-2-pyridinethiones and method of preparing same |
USRE29409E (en) | 1965-03-15 | 1977-09-20 | Ventron Corporation | Phenoxarsine compounds incorporated into resins with phenols |
US3452034A (en) | 1967-03-09 | 1969-06-24 | American Cyanamid Co | Substituted 2-(1,3,4-thiadiazol-2-yl)-4(5)-nitroimidazoles |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
GB2095691A (en) | 1980-08-15 | 1982-10-06 | Scott Bader Co | Coating compositions |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US4596724A (en) | 1984-05-15 | 1986-06-24 | Marine Shield Corp. | Anti-fouling coating composition, process for applying same and coating thereby obtained |
US4568343A (en) | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4788302A (en) | 1985-06-14 | 1988-11-29 | Duke University | Anti-fouling compound and method of use |
US4783450A (en) | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
JPH0653735B2 (ja) | 1987-08-03 | 1994-07-20 | 明治製菓株式会社 | N−アルキルベンゼンスルホニルカルバモイル−5−クロロイソチアゾ−ル誘導体および殺微生物剤 |
ES2077023T3 (es) | 1989-03-10 | 1995-11-16 | Yamanouchi Pharma Co Ltd | Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada. |
US5229124A (en) | 1990-04-02 | 1993-07-20 | Morton International, Inc. | Microbicides immobilized in water soluble thermoplastic resins and aqueous dispersions of microbicides prepared therefrom |
US5194248A (en) * | 1990-06-21 | 1993-03-16 | Trustees Of Boston University | Compositions comprising vitamin D analog precursors and the use thereof |
JPH04325569A (ja) | 1991-04-24 | 1992-11-13 | Ishihara Sangyo Kaisha Ltd | 防汚塗料組成物 |
DE4221255C2 (de) | 1992-06-26 | 1994-09-15 | Lancaster Group Ag | Phospholipide enthaltendes Kosmetikum |
DE4221268C2 (de) | 1992-06-26 | 1997-06-12 | Lancaster Group Ag | Verwendung eines Dermatikums zur Unterstützung des Sauerstofftransportes in der Haut |
US6488912B1 (en) | 1992-07-30 | 2002-12-03 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of dentoalveolar infections with taurolidine and/or taurultam |
US5334389A (en) | 1992-10-15 | 1994-08-02 | Duke University | Antifouling coating and method for using same |
US5384176A (en) | 1992-12-11 | 1995-01-24 | Zimmerman; Richard C. | Phenolic acid sulfate esters for prevention of marine biofouling |
US6086921A (en) | 1995-04-25 | 2000-07-11 | Wintrop-University Hospital | Metal/thiol biocides |
US5928671A (en) | 1995-04-25 | 1999-07-27 | Winthrop University Hospital | Method and composition for inhibiting bacteria |
US6558686B1 (en) | 1995-11-08 | 2003-05-06 | Baylor College Of Medicine | Method of coating medical devices with a combination of antiseptics and antiseptic coating therefor |
US6022498A (en) * | 1996-04-19 | 2000-02-08 | Q2100, Inc. | Methods for eyeglass lens curing using ultraviolet light |
US6071528A (en) | 1997-02-19 | 2000-06-06 | Ultradent Products, Inc. | Adhesive antimicrobial and/or reparative dentin stimulating dental compositions and methods for forming and using such compositions |
US6017936A (en) * | 1997-03-14 | 2000-01-25 | Arch Chemicals, Inc. | Method for producing particles of pyrithione salts and particles so produced |
US5999828A (en) | 1997-03-19 | 1999-12-07 | Qualcomm Incorporated | Multi-user wireless telephone having dual echo cancellers |
US6455031B1 (en) | 1997-06-18 | 2002-09-24 | David G Davies | Methods and compositions for controlling biofilm development |
AU2003204105B2 (en) | 1997-10-28 | 2005-11-17 | Winthrop-University Hospital | Metal/Thiol Biocides |
JPH11158328A (ja) | 1997-11-27 | 1999-06-15 | Fujikura Rubber Ltd | 抗菌性ゴム部品 |
US6380248B1 (en) | 1998-02-04 | 2002-04-30 | Winthrop University Hospital | Metal-thiols as immunomodulating agents |
GB9802355D0 (en) | 1998-02-04 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
US6465015B1 (en) | 1998-02-24 | 2002-10-15 | Arch Chemicals, Inc. | Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles |
TWI245763B (en) | 1998-04-02 | 2005-12-21 | Janssen Pharmaceutica Nv | Biocidal benzylbiphenyl derivatives |
US7108861B1 (en) | 1998-09-23 | 2006-09-19 | Cernofina, Llc | Environmentally benign crop protection agents |
US7521068B2 (en) | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
US6261539B1 (en) * | 1998-12-10 | 2001-07-17 | Akwete Adjei | Medicinal aerosol formulation |
US6682724B2 (en) | 1999-02-23 | 2004-01-27 | Arch Chemcials, Inc. | Sonic method of enhancing chemical reactions to provide uniform, non-agglomerated particles |
JP2000336080A (ja) | 1999-05-28 | 2000-12-05 | Nippon Bayer Agrochem Co Ltd | イソチアゾールカルボキサミド類 |
AU5464901A (en) | 2000-03-01 | 2001-09-12 | Nihon Bayer Agrochem K.K. | Dichloropyridyl- and dichloroisothiazolyl-thiocarboxamides and their use as microbicides |
BR0017361A (pt) | 2000-10-16 | 2004-03-23 | Biocosmetics Sl | Uso de azeite de oliva na preparação de um produto para higiene oral |
US6726898B2 (en) | 2000-11-17 | 2004-04-27 | Gary R. Jernberg | Local delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease |
US6630172B2 (en) | 2001-01-22 | 2003-10-07 | Kareem I. Batarseh | Microbicidal composition containing potassium sodium tartrate |
US6582719B2 (en) | 2001-02-02 | 2003-06-24 | The Trustees Of Columbia University In The City Of New York | Combinations of antiseptic and antibiotic agents that inhibit the development of resistant microorganisms |
CA2441352C (en) | 2001-02-15 | 2010-05-25 | Access Pharmaceuticals, Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
US6555599B2 (en) | 2001-03-26 | 2003-04-29 | Milliken & Company | Antimicrobial vulcanized EPDM rubber articles |
US6448306B1 (en) | 2001-03-23 | 2002-09-10 | Milliken & Company | Antimicrobial articles made from nitrile or natural rubber |
EP1381644A4 (en) | 2001-03-23 | 2005-11-02 | Milliken & Co | ANTIMICROBIAL RUBBER COMPOSITIONS |
US6730324B2 (en) | 2001-04-20 | 2004-05-04 | The University Of British Columbia | Biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
US20030059450A1 (en) | 2001-09-24 | 2003-03-27 | Maibach Howard I. | Method and topical formulation for treating skin conditions associated with aging |
US6638993B2 (en) | 2001-12-12 | 2003-10-28 | Milliken & Company | Colored antimicrobial vulcanized rubber articles |
US6579513B1 (en) | 2002-01-03 | 2003-06-17 | Playtex Products, Inc. | Hygiene mouthspray composition |
US7438925B2 (en) | 2002-08-26 | 2008-10-21 | Biovention Holdings Ltd. | Drug eluting coatings for medical implants |
JP4357166B2 (ja) * | 2002-10-21 | 2009-11-04 | 日揮触媒化成株式会社 | 抗菌・防黴・防藻性組成物 |
US6861049B2 (en) | 2002-11-12 | 2005-03-01 | Douglas B. Harwood | Aqueous slurries useful for cleaning the tongue and throat |
US6848871B1 (en) | 2002-12-19 | 2005-02-01 | Cottrell, Inc. | Strap tie-down system |
WO2008043175A1 (en) | 2006-10-13 | 2008-04-17 | Kane Biotech Inc. | SOLUBLE β-N-ACETYLGLUCOSAMINIDASE BASED ANTIBIOFILM COMPOSITIONS AND USES THEREOF |
JP2004307483A (ja) | 2003-04-07 | 2004-11-04 | Rohm & Haas Co | 殺微生物組成物 |
US6852782B2 (en) | 2003-04-25 | 2005-02-08 | Milliken & Company | Antimicrobial articles and compositions made from non-silicone vulcanized rubber |
US6943205B2 (en) | 2003-04-25 | 2005-09-13 | Milliken & Company | Antimicrobial articles and compositions made from styrene butadiene rubber |
US7060739B2 (en) | 2003-04-25 | 2006-06-13 | Milliken & Company | Antimicrobial fluoroelastomer rubber articles and compositions |
US6875453B2 (en) | 2003-07-18 | 2005-04-05 | Manuel Viamonte, Jr. | Non-toxic disinfectant containing a isopropyl alcohol and sesame oil composition with lemon oil and menthol |
US7381751B2 (en) * | 2003-08-26 | 2008-06-03 | Shantha Sarangapani | Antimicrobial composition for medical articles |
EP1809243B2 (de) * | 2004-07-02 | 2022-06-08 | Boehringer Ingelheim International GmbH | Aerosolsuspensionsformulierungen mit tg 227 ea als treibmittel |
ATE503465T1 (de) | 2004-10-25 | 2011-04-15 | Celonova Biosciences Germany Gmbh | Beladbare polyphosphazenhaltige teilchen für therapeutische und/oder diagnostische anwendungen sowie herstellungs- und verwendungsverfahren dafür |
US7419681B2 (en) | 2004-12-02 | 2008-09-02 | Bioretec, Ltd. | Method to enhance drug release from a drug-releasing material |
US20060205838A1 (en) | 2005-03-10 | 2006-09-14 | Velamakanni Bhaskar V | Hardenable antimicrobial dental compositions and methods |
US7507281B2 (en) | 2005-09-02 | 2009-03-24 | Microban Products Company | Antimicrobial cementitious composition, method and article |
US20070116750A1 (en) | 2005-11-18 | 2007-05-24 | Randall Wolcott | Compositions for disrupting and inhibiting reconstitution of wound biofilm |
US8268395B2 (en) | 2005-12-05 | 2012-09-18 | E. I. Du Pont De Nemours And Company | Method for providing resistance to biofouling in a porous support |
JP4568232B2 (ja) | 2006-01-06 | 2010-10-27 | 秀和 西松 | 人工骨頭保持具 |
JP2007332040A (ja) | 2006-06-12 | 2007-12-27 | Shinshu Univ | カーボンナノチューブを含む抗菌剤とそれを用いた材料及び製剤 |
GB0618697D0 (en) * | 2006-09-22 | 2006-11-01 | Syntopix Ltd | Formulations |
CA2678449C (en) | 2007-01-24 | 2012-09-18 | Cook Incorporated | Biofilm-inhibiting medical products |
US8343536B2 (en) * | 2007-01-25 | 2013-01-01 | Cook Biotech Incorporated | Biofilm-inhibiting medical products |
KR20100017809A (ko) | 2007-05-18 | 2010-02-16 | 아지온 테크놀로지스, 인코포레이티드 | 생물활성 농약 조성물과 이들의 용도 |
JP5642540B2 (ja) | 2007-06-01 | 2014-12-17 | アロウ・インターナショナル・インコーポレイテッドArrow International, Inc. | 組み合わされた線維素溶解性および抗菌性のカテーテル、およびその使用 |
AU2007356895B2 (en) | 2007-07-25 | 2012-11-15 | Varian Medical Systems, Inc. | Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
AU2008345034A1 (en) * | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide - donating compounds and uses thereof |
US20090197003A1 (en) | 2008-02-01 | 2009-08-06 | Thomas Van Zandt | Anti-fouling coatings, Compounds, and methods |
WO2009102787A2 (en) | 2008-02-12 | 2009-08-20 | Boston Scientific Scimed, Inc. | Medical implants with polysaccharide drug eluting coatings |
US20110092589A1 (en) | 2008-03-10 | 2011-04-21 | The Charlotte-Mecklenburg Hospotal Authority | Treatment of Inflammatory Conditions and Diseases with Metal-Thiols |
US9408393B2 (en) | 2010-02-03 | 2016-08-09 | Microbion Corporation | Bismuth-thiols as antiseptics for agricultural, industrial and other uses |
EP2393491B1 (en) * | 2009-02-03 | 2020-04-22 | Microbion Corporation | Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications |
US9028878B2 (en) | 2009-02-03 | 2015-05-12 | Microbion Corporation | Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses |
KR102074444B1 (ko) | 2010-02-03 | 2020-02-06 | 마이크로비온 코포레이션 | 세균 균막의 치료 및 다른 용도를 포함하는, 생의학적 용도를 위한 방부제로서 비스무트-티올 |
-
2010
- 2010-02-03 EP EP10739086.6A patent/EP2393491B1/en active Active
- 2010-02-03 AU AU2010210620A patent/AU2010210620B2/en active Active
- 2010-02-03 US US12/699,680 patent/US8389021B2/en active Active
- 2010-02-03 BR BRPI1007885A patent/BRPI1007885A2/pt not_active Application Discontinuation
- 2010-02-03 WO PCT/US2010/023108 patent/WO2010091124A2/en active Application Filing
- 2010-02-03 EP EP20163101.7A patent/EP3695835A1/en active Pending
- 2010-02-03 JP JP2011548426A patent/JP5674684B2/ja active Active
- 2010-02-03 CN CN201080009333.0A patent/CN102341105B/zh active Active
- 2010-02-03 CA CA2751386A patent/CA2751386C/en active Active
-
2012
- 2012-07-31 HK HK12107475.5A patent/HK1166707A1/xx unknown
-
2013
- 2013-03-01 US US13/782,963 patent/US20130171210A1/en not_active Abandoned
-
2014
- 2014-09-08 JP JP2014182123A patent/JP2015007113A/ja active Pending
-
2018
- 2018-07-31 US US16/050,038 patent/US10835510B2/en active Active
-
2020
- 2020-10-05 US US17/063,491 patent/US11564903B2/en active Active
-
2023
- 2023-01-18 US US18/098,466 patent/US20230149340A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2012516855A5 (ja) | ||
JP2013518895A5 (ja) | ||
US10596109B2 (en) | Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases | |
RU2013110493A (ru) | Висмут-тиолы в качестве антисептиков для сельскохозяйственных, промышленных и других применений | |
US20230277489A1 (en) | Intermediate metabolism products to potentiate aminoglycoside antibiotics in bacterial infections | |
US20210236541A1 (en) | Iodophor composition with improved stability in the presence of organic material | |
JP2017125031A (ja) | 3−ブロモピルバートおよび他のatp産生の選択的阻害剤を用いる処置の方法 | |
JP2017513839A (ja) | 凍結融解後に薬物ナノ結晶を形成するリポソーム | |
WO2012151474A2 (en) | Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria | |
EP3502093A1 (en) | Zwitterionic pillararene derivative | |
KR20110059725A (ko) | 세프타롤린을 포함하는 조성물 및 치료 방법 | |
Hasani et al. | Metal nanoparticles and consequences on multi-drug resistant bacteria: reviving their role | |
da Silva et al. | Highlights regarding the use of metallic nanoparticles against pathogens considered a priority by the world health organization | |
JP2012518036A (ja) | 肺送達のためのpH調節された製剤 | |
CA2968135A1 (en) | Combination therapy effective against microorganisms, including drug resistant microorganisms | |
WO2014117755A1 (en) | Antibiotic preparation and use thereof | |
US8309554B2 (en) | Hypoxia activated drugs of nitrogen mustard alkylators | |
JP2010095489A (ja) | 病原性細菌の毒素産生抑制剤 | |
JP2017538675A (ja) | 微生物感染を治療するための相乗的組成物 | |
Safari et al. | Novel surface biochemical modifications of urinary catheters to prevent catheter‐associated urinary tract infections | |
WO2019104213A1 (en) | Antibiofilm formulations and use thereof | |
US20190046467A1 (en) | Compositions and methods for inhibiting biofilm-forming bacteria | |
Chirra et al. | Antimicrobial Efficacy and Targeted Nanoparticle Delivery of Silver Ibuprofen to Treat Multi-Drug Resistant Gram-Positive and Gram-Negative Pathogens | |
Ayaz | Responsive Multilayer and Hydrogel Based Drug for Resisting Bacterial Infection | |
Bush | Plazomicin |